Back
 Health  Vol.8 No.5 , March 2016
Hepatitis B Virus Infection in B-Cell Non-Hodgkin’s Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy
Abstract: Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin’s Lymphoma) are limited, as well as prophylactic antiviral therapy for B-NHL patients with HBV infection who are receiving anticancer chemotherapy. This study aims to investigate the association between HBV infection and B-NHL, and to evaluate the effect of prophylactic antiviral therapy for HBV-infected B-NHL patients. Study design: A retrospective, case-control study was performed. The study group included 420 patients with B-NHL who were consecutively diagnosed from May 2003 to October 2013 (age range, 14 - 71 years), and the control group included 1280 Chinese residents in Guangxi who participated in the Health Survey (age range, 18 - 74 years). We compared the prevalence rate of HBV infection and clinic-pathologic characteristics between the two groups. The prevalence rate of HBV infection in our study was 34.7% (146/420), higher than the prevalence rate of 13.9% (178/1280) in the general population (P < 0.001). Among 146 B-NHL patients who received anticancer chemotherapy, 104 patients (71.2%) received prophylactic antiviral therapy. Conclusion: This study provides evidence that HBV may play an important role in development of B-NHL. Entecavir maybe the better antiviral drugs than Lamivudine, and antiviral therapy is maintained more than 6 months that maybe the optimal duration of prophylactic antiviral therapy. But further investigation should be conducted for determination of optimal duration and monitoring of antiviral therapy.
Cite this paper: Chen, J. , Yi, H. , Cen, H. and Yan, W. (2016) Hepatitis B Virus Infection in B-Cell Non-Hodgkin’s Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy. Health, 8, 495-503. doi: 10.4236/health.2016.85053.
References

[1]   Lee, W.M. (1997) Hepatitis B Virus Infection. The New England Journal of Medicine, 337, 1733-1745.
http://dx.doi.org/10.1056/NEJM199712113372406

[2]   Liaw, Y.F. and Chu, C.M. (2009) Hepatitis B Virus Infection. The Lancet, 373, 582-592.
http://dx.doi.org/10.1016/S0140-6736(09)60207-5

[3]   Parkin, D.M. (2006) The Global Health Burden of Infection-Associated Cancers in the Year 2002. International Journal of Cancer, 118, 3030–3044.
http://dx.doi.org/10.1002/ijc.21731

[4]   Li, Y.H., He, Y.F. and Jiang, W.Q. (2006) Lamivudine Prophylaxis Reduces the Incidence and Severity of Hepatitis in Hepatitis B Virus Carriers Who Receive Chemotherapy for Lymphoma. Cancer, 106, 1320-1325.
http://dx.doi.org/10.1002/cncr.21701

[5]   Muller, A.M., Ihorst,G. and Mertelsmann, R. (2005) Epidemiology of Non-Hodgkin’s Lymphoma (NHL): Trends, Geographic Distribution, and Etiology. Annals of Hematology, 84, 1-12.
http://dx.doi.org/10.1007/s00277-004-0939-7

[6]   Parkin, D.M., Bray, F. and Ferlay, J. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108.
http://dx.doi.org/10.3322/canjclin.55.2.74

[7]   Cucuianu, A., Patiu, M. and Duma, M. (1999) Hepatitis B and C Virus Infection in Romanian Non-Hodgkin’s Lymphoma Patients. British Journal of Haematology, 107, 353-356.
http://dx.doi.org/10.1046/j.1365-2141.1999.01692.x

[8]   Kim, J.H., Bang, Y.-J., Park, B.J., Yoo, T., Kim, C.W., Kim, T.Y., Heo, D.S., Lee, H.-S. and Kim, N.K. (2002) Hepatitis B Virus Infection and B-Cell Non-Hodgkin’s Lymphoma in a Hepatitis B Endemic Area: A Case-Control Study. Japanese Journal of Cancer Research, 93, 471-477.
http://dx.doi.org/10.1111/j.1349-7006.2002.tb01280.x

[9]   He, H., Zhai, M. and Zhang, D. (2003) Clinical Significance of Detecting Serum Label of Hepatitis B Virus in NHL Patients. Journal of Chinese Clinical Medicine, 4, 8-10.

[10]   Kuniyoshi, M., Nakamuta, M. and Sakai, H. (2001) Prevalence of Hepatitis B or C Virus Infections in Patients with Non-Hodgkin’s Lymphoma. Journal of Gastroenterology and Hepatology, 16, 215-219.
http://dx.doi.org/10.1046/j.1440-1746.2001.02406.x

[11]   Yoffe, B., Noonan, C.A., Melnick, J.L. and Hollinger, F. (1986) Hepatitis B Virus DNA in Mononuclear Cells and Analysis of Cell Subsets for the Presence of Replicative Intermediates of Viral DNA. The Journal of Infectious Diseases, 153, 471-477.
http://dx.doi.org/10.1093/infdis/153.3.471

[12]   Bronowicki, J.P., Loriot, M.A., Thiers, V., Grignon, Y., Zignego, A.L. and Bréchot, C. (1998) Hepatitis C Virus Persistence in Human Hematopoietic Cells Injected into SCID Mice. Hepatology, 28, 211-218.
http://dx.doi.org/10.1002/hep.510280127

[13]   Musto, P. (2002) Hepatitis C Virus Infection and B-Cell non-Hodgkin’s Lymphomas: More than a Simple Association. Clinical Lymphoma, 3, 150-160.
http://dx.doi.org/10.3816/CLM.2002.n.021

[14]   Negri, E., Little, D., Boiocchi, M., La Vecchia, C. and Franceschi, S. (2004) B-Cell Non-Hodgkin’s Lymphoma and Hepatitis C Virus Infection: A Systematic Review. International Journal of Cancer, 111, 1-8.
http://dx.doi.org/10.1002/ijc.20205

[15]   Dal Maso, L. and Franceschi, S. (2006) Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-Analysis of Epidemiologic Studies. Cancer Epidemiology, Biomarkers & Prevention, 15, 2078-2085.
http://dx.doi.org/10.1158/1055-9965.EPI-06-0308

[16]   Dal Maso, L., Talamini, R., Montella, M., Crovatto, M. and Franceschi, S. (2004) Hepatitis B and C Viruses and Hodgkin Lymphoma: A Case-Control Study from Northern and Southern Italy. Haematologica, 89, e141-e142.

[17]   Gentile, G., Mele, A., Monarco, B., Vitale, A., Pulsoni, A., Visani, G., Castelli, G., Rapicetta, M., Verani, P., Martino, P. and Mandelli, F. (1996) Hepatitis B and C Viruses, Human T-Cell Lymphotropic Virus Types I and II, and Leukemias: A Case-Control Study. The Italian Leukemia Study Group. Cancer Epidemiology, Biomarkers & Prevention, 5, 227-230.

[18]   Kwag, J.Y., Jung, S.H., Kang, Y.K., Han, C.J., Kim, Y.C. and Lee, J.O. (2000) Acute Exacerbation of Hepatitis in Hepatitis B Virus Carriers with Non-Hodgkin’s Lymphoma after Chemotherapy Korean. Journal of Gastroenterology, 35, 64-72.

[19]   Ku, B.K., Hahn, J.S., Hahn, K.H., Lee, S.T., Suh, H.C. and Kwon, K.H. (1997) Clinical Outcome of the HBsAg Positive Malignant Lymphoma Patients Following Anticancer Chemotherapy. The Korean Journal of Medicine, 52, 542- 549.

[20]   Lalazar, G., Rund, D. and Shouval, D. (2007) Screening, Prevention and Treatment of Viral Hepatitis B Reactivation in Patients with Haematological Malignancies. British Journal of Haematology, 36, 699-712.
http://dx.doi.org/10.1111/j.1365-2141.2006.06465.x

[21]   Lau, G.K. (2008) Hepatitis B Reactivation after Chemotherapy: Two Decades of Clinical Research. Hepatology International, 2, 152-162.
http://dx.doi.org/10.1007/s12072-008-9056-3

[22]   Ziakas, P.D., Karsaliakos, P. and Mylonakis, E. (2009) Effect of Prophylactic Lamivudine for Chemotherapy-Associated Hepatitis B Reactivation in Lymphoma: A Meta-Analysis of Published Clinical Trials and a Decision Tree Addressing Prolonged Prophylaxis and Maintenance. Haematologica, 94, 998-1005.
http://dx.doi.org/10.3324/haematol.2009.005819

[23]   Lau, G.K., Yiu, H.H., Fong, D.Y., Cheng, H.C., Au, W.Y. and Lai, L.S. (2003) Early Is Superior to Deferred Preemptive Lamivudine Therapy for Hepatitis B Patients Undergoing Chemotherapy. Gastroenterology, 125, 1742-1749.
http://dx.doi.org/10.1053/j.gastro.2003.09.026

[24]   Artz, A.S., Somerfield, M.R., Feld, J.J., Giusti, A.F., Kramer, B.S. and Sabichi, A.L. (2010) American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases. Journal of Clinical Oncology, 28, 3199-3202.
http://dx.doi.org/10.1200/JCO.2010.30.0673

[25]   Kim, Y.M., Jeong, S.-H., Kim, J.-W., Lee, S.H., Hwang, J.H., Park, Y.S., Kim, N., Lee, J.S., Kim, H.Y. and Lee, D.H. (2011) Chronic Hepatitis B, Non-Hodgkin’s Lymphoma, and Effect of Prophylactic Antiviral Therapy. Journal of Clinical Virology, 51, 237-241.

[26]   Lok, A.S. and McMahon, B.J. (2001) Chronic Hepatitis B. Hepatology, 34, 1225-1241.
http://dx.doi.org/10.1053/jhep.2001.29401

[27]   Hsu, C., Hsiung, C.A., Su, I.J., Hwang, W.S., Wang, M.C. and Lin, S.F. (2008) A Revisit of Prophylactic Lamivudine for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma: A Randomized Trial. Hepatology, 47, 844-853.
http://dx.doi.org/10.1002/hep.22106

[28]   Engels, E.A., Cho, E.R. and Jee, S.H. (2010) Hepatitis B Virus Infection and Risk of Non-Hodgkin Lymphoma in South Korea: A Cohort Study. The Lancet Oncology, 11, 827-834.
http://dx.doi.org/10.1016/S1470-2045(10)70167-4

[29]   Yood, M.U., Quesenberry Jr., C.P., Guo, D., Caldwell, C., Wells, K., Shan, J., Sanders, L., Skovron, M.L., Iloeje, U. and Manos, M.M. (2007) Incidence of Non-Hodgkin’s Lymphoma among Individuals with Chronic Hepatitis B Virus Infection. Hepatology, 46, 107-112.
http://dx.doi.org/10.1002/hep.21642

[30]   Kang, J., Cho, J.H., Suh, C.W., Lee, D.H., Oh, H.B. and Sohn, Y.H. (2010) High Prevalence of Hepatitis B and Hepatitis C Virus Infections in Korean Patients with Hematopoietic Malignancies. Annals of Hematology, 90, 159-164.
http://dx.doi.org/10.1007/s00277-010-1055-5

[31]   Lim, S.-T., Fei, G., Quek, R., Lim, L.-C., Lee, L.-H., Yap, S.-P., Loong, S. and Tao, M. (2007) The Relationship of Hepatitis B Virus Infection and Non-Hodgkin’s Lymphoma and Its Impact on Clinical Characteristics and Prognosis. European Journal of Haematology, 79, 132-137.
http://dx.doi.org/10.1111/j.1600-0609.2007.00878.x

[32]   Pontisso, P., Morsica, G., Ruvoletto, M.G., Zam-bello, R., Colletta, C. and Chemello, L. (1991) Hepatitis B Virus Binds to Peripheral Blood Mononuclear Cells via the Pre S1 Protein. Journal of Hepatology, 12, 203-206.
http://dx.doi.org/10.1016/0168-8278(91)90939-9

[33]   Murakami, Y., Minami, M., Daimon, Y. and Okanoue, T. (2004) Hepatitis B Virus DNA in Liver, Serum, and Peripheral Blood Mononuclear Cells after the Clearance of Serum Hepatitis B Virus Surface Antigen. Journal of Medical Virology, 72, 203-214.
http://dx.doi.org/10.1002/jmv.10547

[34]   Umeda, M., Marusawa, H., Seno, H., Katsurada, A., Nabeshima, M. and Egawa, H. (2005) Hepatitis B Virus Infection in Lymphatic Tissues in Inactive Hepatitis B Carriers. Journal of Hepatology, 42, 806-812.
http://dx.doi.org/10.1016/j.jhep.2005.01.016

[35]   Stoll-Becker, S., Repp, R., Glebe, D., Schaefer, S., Kreuder, J. and Kann, M. (1997) Transcription of Hepatitis B Virus in Peripheral Blood Mononuclear Cells from Persistently Infected Patients. Journal of Virology, 71, 5399-5407.

[36]   Pontisso, P., Vidalino, L., Quarta, S. and Gatta, A. (2008) Biological and Clinical Implications of HBV Infection in Peripheral Blood Mononuclear Cells. Autoimmunity Reviews, 8, 13-17.
http://dx.doi.org/10.1016/j.autrev.2008.07.016

[37]   Hoofnagle, J.H., Dusheiko, G.M. and Schafer, D.F. (1982) Reactivation of Chronic Hepatitis B Virus Infection by Cancer Chemotherapy. Annals of Internal Medicine, 96, 447-449.
http://dx.doi.org/10.7326/0003-4819-96-4-447

[38]   Rossi, G., Pelizzari, A., Motta, M. and Puoti, M. (2001) Primary Prophylaxis with Lamivudine of Hepatitis B Virus Reactivation in Chronic HbsAg Carriers with Lymphoid Malignancies Treated with Chemotherapy. British Journal of Haematology, 15, 58-62.
http://dx.doi.org/10.1046/j.1365-2141.2001.03099.x

[39]   Vassiliadis, T., Garipidou, V. and Tziomalos, K. (2005) Prevention of Hepatitis B Reactivation with Lamivudine in Hepatitis B Virus Carriers with Hematologic Malignancies Treated with Chemotherapy—A Prospective Case Series. American Journal of Hematology, 80, 197-203.
http://dx.doi.org/10.1002/ajh.20471

[40]   Yeo, W., Chan, P.K. and Ho, W.M. (2004) Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B Santigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy. Journal of Clinical Oncology, 22, 927-934.
http://dx.doi.org/10.1200/JCO.2004.05.161

[41]   Dai, M.S., Chao, T.Y., Kao, W.Y., Shyu, R.Y. and Liu, T.M. (2004) Delayed Hepatitis B Virus Reactivation after Cessation of Preemptive Lamivudine in Lymphoma Patients Treated with Rituximab plus CHOP. Annals of Hematology, 83, 769-774.
http://dx.doi.org/10.1007/s00277-004-0899-y

[42]   Hui, C.K., Cheung, W.W., Au, W.Y., Lie, A.K., Zhang, H.Y. and Yueng, Y.H. (2005) Hepatitis B Reactivation after Withdrawal of Pre-Emptive Lamivudine in Patients with Haematological Malignancy on Completion of Cytotoxic Chemotherapy. Gut, 54, 1597-1603.
http://dx.doi.org/10.1136/gut.2005.070763

[43]   Lok, A.S. and McMahon, B.J. (2004) Chronic Hepatitis B: Update of Recommendations. Hepatology, 39, 857-861.
http://dx.doi.org/10.1002/hep.20110

[44]   European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. Journal of Hepatology, 50, 227-242.
http://dx.doi.org/10.1016/j.jhep.2008.10.001

[45]   Lee, K.S. and Kim, D.J. (2007) Management of Chronic Hepatitis B. Korean Journal of Hepatology, 13, 447-488.
http://dx.doi.org/10.3350/kjhep.2007.13.4.447

 
 
Top